search icon
  • Print
  • ShareThis
  • Text Size
  • Continuing Medical Education Credit for CID/JID/OFID Manuscript Reviewers

    The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.

    The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.

    To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.

    You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.

    Accreditation Statement

    The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM.  Physicians should only claim credit commensurate with the extent of their participation in the activity.  Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.


    Through the manuscript peer review process for CID, JID, or OFID, you should be able to:

    • integrate new discoveries or observations in infectious disease research that can be applied in your work
    • use information resources that improve your ability to treat patients or to conduct research in infectious diseases
    • identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
    • apply new information that could result in improved healthcare outcomes

    Disclosure Information 

    In compliance with ACCME's Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.

    CID Editors Disclosures 


    Sherwood L. Gorbach: Employee (part-time): Cubist Pharmaceuticals, Inc.; Advisory Board/Consultant/Stockholder: Cempra Pharmaceuticals, Seres Health


    Deputy Editors

    Michael Barza: Employee: Steward Carney Hospital, Tufts Medical Center; shareholder: Abbott Labs, Abbvie.

    Sara Cosgrove: Employee: Johns Hopkins University School of Medicine' Advisory Board/Consultant: Novartis; Grants (through institution): Pfizer Grants for Learning and Change


    Associate Editors

    Barbara Alexander: Employee: Duke University; Grants (through institution): Astellas, Charles River Labs, Pfizer, Scynexis, Viamet; Site investigator for clinical trial: Cubit, Virapharma 

    Neil Blacklow: Stockholder: BristolMyersSquibb 

    Donald Goldmann: Employee: Institute for Healthcare Improvement

    Camilla Graham: Employee: Beth Israel Deaconess Medical Center, Up To Date

    John R. Graybill: Nothing to disclose

    A.W.Karchmer: Employee: Beth Israel Deaconess Medical Center; Advisory Board/Consultant: Debiopharma, Merck, Pfizer, Cubist; Stockholder: Optimer; Johnson and Johnson, Pfizer, E. Lilly, Arena Pharmaceuticals, Amgen, Gilead; Grants: Theravance 

    Jerry Klein: Employee: Boston University School of Medicine; Advisory Board/Consultant: Save the Children, GlaxoSmithKline Vaccines, Optimer 

    Robert Schooley: Employee: University of California, San Diego; Advisory Board/Consultant: Theraclone, Santaris, CytoDyn, Merck; Honoraria: AASLD, University of Singapore; Grants: Boehringer-Ingelheim, Merck; Grants (through institution): Gilead Sciences, Globelmmune, Monogram Biosciences

    Cynthia Sears: Grants: Merieux Institute

    Lucy Tompkins: Employee: Stanford University; Advisory Board/Consultant (and stockholder): iSense, Inc.

    Chris Wanke: Employee: Pratt Physician Group; Advisory Board/Consultant: Pfizer, Cubist; Clinical Trial: GlaxoSmithKline; Patent: Parr

    JID Editors Disclosures

    Associate Editors

    Ann Arvin: Consultant: GlaxoSmithKline, Novartis, Merck, Vaxart 

    Marcel Behr: Nothing to disclose

    Raymund Chung: Grants: Gilead, Mass Biologics, Vertex; Consultant: Abbvie, Idenix 

    Peter Densen: Nothing to disclose

    Joseph Kovacs: Nothing to disclose

    Daniel Kuritzkes: Grant: Gilead, Merck; Consultant: Bristol-Myers Squibb, Celera, Gilead, GlaxoSmithKline, InnaVirVax, Koronis, Boehrunger-Ingelheim, Merck, Tobira, ViiV; Honoraria: Roche, Gilead and ViiV 

    Stuart Levitz: Nothing to disclose

    William Schaffner: Consultant: Sanofi-Pasteur, Dynavax, Pfizer; Data Safety Monitoring Board: Merck

    Jane Schwebke: Grants: Hologic/GenProbe, Akesis, BD Diagnostics, Cepheid, Quidel, Symbiomix, StarPharma; Consultant: Akesis, Hologic/GenProbe 

    Peter Weller: Advisory Board: GlaxoSmithKline 

    Richard Whitley: Board of Directors: Gilead Sciences; Honoraria: Roche-IRIS Expert Panel; Consulting: N&N Pharmaceuticals, Merck Data Safety and Monitoring Board, GlaxoSmithKline-Watermark Data Safety Monitoring Board


    Statistical Editors

    Michael Hughes: Data Safety and Monitoring Board (paid): Boehringer-Ingelhiem, Medicines Development, Pfizer, Tibotec 

    Sarah Walker: Grant:ViiV/GlaxoSmithKline; Speaker Fee: Gilead  Sciences

    OFID Editors Disclosures

    Editor in Chief

    Paul Sax: Consultant: AbbVie, BMS, Gilead, GSK/ViiV, Janssen, Merck; Grants: BMS, Gilead, GSK/ViiV, Merck


    Associate Editors

    Johanna Daily: Nothing to disclose

    Jonathan Blum: Nothing to disclose

    Jonathan Li: Consultant: TherapyEdge, SeraCare Life Sciences; Grants: Gilead Sciences

    Keith Kaye: Consultant:  Merck, Actavis, The Medicines Company; Grants: Merck, Actavis; Speakers bureau: Actavis

    Kimberley Hanson: Consultant: Astellas, BioFire

    Maunank Shah: Consultant: World Health Organization (WHO)










| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site